Avantor, Inc. (NYSE:AVTR) Given Average Rating of “Hold” by Analysts

Shares of Avantor, Inc. (NYSE:AVTR) have been assigned an average recommendation of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $13.60.

Several equities research analysts have recently weighed in on AVTR shares. Evercore ISI set a $12.00 target price on shares of Avantor and gave the stock an “in-line” rating in a research report on Monday, January 5th. Barclays reiterated an “equal weight” rating and issued a $12.00 price target (down from $15.00) on shares of Avantor in a research note on Thursday, October 30th. Jefferies Financial Group cut Avantor to an “underperform” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $12.00 target price (down previously from $14.00) on shares of Avantor in a report on Thursday, October 30th. Finally, UBS Group set a $12.00 price target on Avantor in a report on Thursday, October 30th.

Insiders Place Their Bets

In other Avantor news, Director Sanjeev K. Mehra bought 350,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were bought at an average cost of $11.09 per share, with a total value of $3,881,500.00. Following the completion of the acquisition, the director owned 350,000 shares of the company’s stock, valued at approximately $3,881,500. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Voss Capital LP bought a new stake in shares of Avantor during the second quarter valued at approximately $6,057,000. ABS Direct Equity Fund LLC bought a new position in Avantor in the 3rd quarter worth approximately $1,248,000. Tredje AP fonden increased its position in Avantor by 110.7% in the 2nd quarter. Tredje AP fonden now owns 110,981 shares of the company’s stock valued at $1,494,000 after acquiring an additional 58,304 shares during the period. Squarepoint Ops LLC bought a new stake in Avantor during the 2nd quarter valued at $2,055,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Avantor during the 3rd quarter valued at $1,208,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Stock Performance

Avantor stock opened at $10.81 on Friday. Avantor has a 52 week low of $10.62 and a 52 week high of $22.73. The company has a current ratio of 1.49, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. The stock has a market cap of $7.37 billion, a P/E ratio of -83.15, a price-to-earnings-growth ratio of 3.83 and a beta of 0.93. The stock has a 50 day moving average of $11.59 and a 200-day moving average of $12.43.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.01). Avantor had a negative net margin of 1.25% and a positive return on equity of 10.91%. The company had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period in the prior year, the company earned $0.26 earnings per share. The company’s revenue was down 5.3% on a year-over-year basis. On average, analysts expect that Avantor will post 1.06 EPS for the current fiscal year.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.